DA
ANAB icon

DCF Advisers’s AnaptysBio ANAB Stock Holding History

DCF Advisers’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04M Sell
18,775
-16,475
-47% -$886K 0.28% 59
2025
Q4 		$1.71M Sell
35,250
-12,750
-27% -$497K 0.46% 54
2025
Q3 		$1.47M Hold
48,000
– – 0.47% 54
2025
Q2 		$1.07M Buy
48,000
+13,150
+38% +$275K 0.49% 52
2025
Q1 		$648K Buy
+34,850
New +$581K 0.31% 64

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DCF Advisers's ANAB Position: Q1 2026 in Review

DCF Advisers reduced its AnaptysBio (ANAB) stake by 47% in Q1 2026, selling an estimated $886K and leaving 18,775 shares worth $1.04M. The position accounts for 0.28% of the portfolio, ranked #59.

DCF Advisers first reported a position in ANAB in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.71M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • DCF Advisers held 18,775 shares of AnaptysBio worth $1.04M as of Q1 2026.
  • DCF Advisers sold 16,475 AnaptysBio shares in Q1 2026, an estimated $886K.
  • AnaptysBio made up 0.28% of DCF Advisers's portfolio in Q1 2026, its #59 holding.
  • DCF Advisers first reported a position in AnaptysBio in Q1 2025 and has held it in 5 quarters since.
  • DCF Advisers's AnaptysBio position peaked at $1.71M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.